Harbor Capital Advisors Inc. Takes $1.27 Million Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ)

Harbor Capital Advisors Inc. acquired a new stake in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 43,989 shares of the company's stock, valued at approximately $1,270,000. Harbor Capital Advisors Inc. owned about 0.16% of LENZ Therapeutics at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. State Street Corp increased its holdings in LENZ Therapeutics by 18.7% during the 3rd quarter. State Street Corp now owns 289,154 shares of the company's stock worth $6,865,000 after purchasing an additional 45,600 shares in the last quarter. Parkman Healthcare Partners LLC bought a new stake in LENZ Therapeutics during the third quarter worth $3,308,000. Charles Schwab Investment Management Inc. raised its position in LENZ Therapeutics by 197.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 123,371 shares of the company's stock valued at $2,929,000 after buying an additional 81,901 shares during the last quarter. Renaissance Technologies LLC lifted its stake in LENZ Therapeutics by 28.4% during the 2nd quarter. Renaissance Technologies LLC now owns 60,166 shares of the company's stock valued at $1,040,000 after acquiring an additional 13,300 shares in the last quarter. Finally, BBR Partners LLC boosted its holdings in LENZ Therapeutics by 100.0% during the 3rd quarter. BBR Partners LLC now owns 40,000 shares of the company's stock worth $950,000 after acquiring an additional 20,000 shares during the last quarter. 54.32% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

LENZ has been the subject of several analyst reports. HC Wainwright reiterated a "buy" rating and issued a $38.00 price objective on shares of LENZ Therapeutics in a research note on Thursday, November 7th. Raymond James started coverage on LENZ Therapeutics in a report on Friday, September 27th. They set an "outperform" rating and a $37.00 price target on the stock. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, LENZ Therapeutics has a consensus rating of "Buy" and an average price target of $35.40.

LENZ Therapeutics Stock Performance

Shares of LENZ traded up $0.03 during mid-day trading on Monday, hitting $23.24. The stock had a trading volume of 90,151 shares, compared to its average volume of 145,324. LENZ Therapeutics, Inc. has a 52 week low of $14.42 and a 52 week high of $38.93. The business has a fifty day moving average price of $32.37 and a 200-day moving average price of $26.28.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.47) by $0.09. During the same period in the prior year, the firm earned ($1.33) earnings per share. On average, equities research analysts forecast that LENZ Therapeutics, Inc. will post -2.09 EPS for the current year.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.